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A 63 year old woman visits her doctor with a three month history
of fatigue and generalised joint pains. Her medical history is
unremarkable and she reports no recent stress, infection, or
weight loss. There are no abnormalities on clinical examination.
Haemoglobin, creatinine, and electrolytes, liver enzymes,
glucose, inflammatory markers, and thyroid function tests are
normal. Ferritin, iron, transferrin, and transferrin saturation are
also requested.
This article discusses some situations in which ferritin and iron
studies might be helpful and how to avoid common pitfalls in
their interpretation.
What are the next investigations?
The doctor in this case requested iron studies to investigate the
possibility of iron overload and to screen for haemochromatosis.
Iron studies are also commonly indicated in clinical practice to
investigate iron deficiency, or to monitor response to treatment
for these conditions (box 1).
Conventional laboratory tests of iron status are often referred
to as “iron studies.” They include tests for serum ferritin, iron,
transferrin, or total iron binding capacity (TIBC), and transferrin
saturation.
Iron is a key component of haemoglobin in red blood cells,
myoglobin in muscle, and many metalloproteins and enzymes.
It is essential for uptake of oxygen and its delivery to tissues,
utilisation of oxygen by muscle cells, and mitochondrial energy
production.3 Normal iron metabolism and regulation is outlined
in Figure 1⇓. The adult male body contains 3-5 g of iron. Less
than 0.1% of total body iron stores circulate in plasma. Dietary
Fe3+ is reduced to Fe2+ and transported into the enterocyte by
the divalent metal transporter DMT1. Iron is exported across
the basolateral membrane via the iron export protein ferroportin
1 or stored as ferritin. Transferrin bound iron binds to transferrin
receptor 1 (TFR1) and is taken up into the cell via receptor
mediated endocytosis. Expression of TFR1 is regulated locally
by the iron demands of the cell, via binding of iron regulatory
proteins. Old or damaged erythrocytes are removed from the
circulation by splenic macrophages. Iron is removed from haem
by haem oxygenase 1, and either stored as ferritin or released
into the circulation.
Regulation of iron release at a systemic level is mediated by the
peptide hormone hepcidin (produced predominantly by
hepatocytes) and has an inhibitory effect on iron release from
cells and dietary iron absorption. Expression is controlled by
complex signalling pathways.1
What is included in iron studies?
Ferritin—is the intracellular storage form of iron. A very small
amount is found in serum. In inflammation, liver disease, and
malignancy, ferritin levels can rise because ferritin is an acute
phase protein.4 In these patients, ferritin can appear either falsely
high or normal, when in reality stores are low.
Serum iron—refers to ferric ions (Fe3+) bound to serum
transferrin. Serum iron concentration is highly variable and is
affected by dietary iron intake, inflammation, and infection.5
Transferrin—is the principal iron transport protein in plasma.
It increases in iron deficiency to maximise utilisation of
available iron.4 Total iron binding capacity is an alternative test
to transferrin. TIBC reflects the availability of iron binding sites
on transferrin. Values increase in iron deficiency and decrease
in iron overload. Some laboratories measure unsaturated iron
binding capacity (UIBC) and calculate TIBC by adding serum
iron to UIBC.
Transferrin saturation—is calculated from serum iron and either
TIBC or transferrin measurements. Typically, transferrin is 30%
saturated with iron.5 Transferrin saturation rises in iron overload
and falls in iron deficiency, but does not quantitatively reflect
iron stores.1 A rise in serum iron due to dietary iron intake can
cause raised transferrin saturation.
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What you need to know
•Iron overload typically results in a high ferritin and transferrin saturation
•Iron deficiency is best assessed using serum ferritin, which is low in the absence of inflammation
•Ferritin levels can be elevated by inflammatory processes and can mask iron deficiency
Box 1: Suggested indications for iron studies
Investigation of
• iron overload (haemochromatosis)1
o at early stages can be asymptomatic or present with vague symptoms such as fatigue, weakness, or generalised joint pains
o later manifestations might include deranged liver enzymes, cirrhosis, erectile dysfunction, arthritis, or cardiomyopathy
o suspected iron overdose/toxicity
• iron deficiency2
o investigating aetiology of low haemoglobin
o symptoms of anaemia—such as lethargy, shortness of breath, palpitations, pallor, headache, atrophic glossitis, angular cheilosis.
Suspected occult blood loss in males and post menopausal females—eg, peptic ulcer disease
o menorrhagia
o iron malabsorption—eg, investigation of unintentional weight loss or chronic diarrhoea, or secondary to existing conditions such as
coeliac disease
o Anaemia in pregnancy (increased iron demands)
o investigation of poor growth in infants
o distinguishing low iron stores from functional iron deficiency—eg, in chronic kidney disease
• response to medical treatment
o monitoring patients who require repeated transfusions or venesection
o monitoring response to iron chelators
o assessing response to iron therapy
Interpretation
Interpretation of iron studies can be challenging because the
difficulties listed above affect almost all markers of iron status.
Nevertheless, iron studies play an important role in clinical
assessment (table 1⇓). Reference intervals are quoted; however,
these can vary by laboratory and must be confirmed locally.
Iron overload
Testing for iron overload (increased total body iron stores with
or without organ dysfunction) can be triggered by clinical
features such as those listed in box 1. Primary iron overload
includes inherited mutations in iron regulatory genes (causing
iron loading syndromes such as haemochromatosis). Secondary
iron overload is associated with other conditions or iatrogenic
factors (box 2).
Hereditary haemochromatosis (an autosomal recessive genetic
condition caused by mutation of the HFE gene) is the most
common inherited cause of iron overload. Homozygosity for
the C282Y polymorphism affects 1 in 200 people of northern
European descent and accounts for more than 80% of clinically
recognised cases. Clinical penetrance varies widely (1%-28%
of C282Y homozygotes in population studies).7 In an unselected
population, raised serum ferritin (>200 μg/L for premenopausal
women or >300 μg/L for men and postmenopausal women) and
transferrin saturation >50% diagnosed C282Y homozygosity
with a sensitivity of 90% in men and 75% in women.8 An
approach to hyperferritinaemia has previously been discussed.6
Specialist techniques for assessing iron overload include liver
biopsy, magnetic resonance imaging, and superconducting
quantum interference device susceptometry, a non-invasive
technique that measures the amount of in vivo magnetisation
caused by hepatic iron.1 Indications for these tests can include
marked hyperferritinaemia (>1000 μg/L) or further assessment
when the diagnosis of iron overload is in doubt. They are not
widely available and are usually requested by specialists.
Tips on requests and interpretation
•Request serum ferritin and transferrin saturation together
to assess for iron overload, alongside haemoglobin to
identify anaemia and aid treatment decisions (eg,
venesection).
• If elevated transferrin saturation is the only biochemical
abnormality or the result is borderline, repeat the test on a
fasting sample to eliminate a rise caused by dietary iron.
• If transferrin saturation is persistently raised, offer HFE
gene analysis with pre-test counselling.
• In C282Y homozygotes, transferrin saturation is the first
biochemical parameter to rise. Serum ferritin might be
normal in the early stages of the disease, however some
patients later develop clinically significant iron overload7
(organ dysfunction with or without symptoms). Annual
monitoring of serum ferritin is proposed in established
guidelines.1 In the absence of local defined protocols,
consider referral for further assessment if
hyperferritinaemia develops or ferritin is progressively
rising.
• Ingestion of therapeutic iron (including iron containing
multivitamins) can raise transferrin saturation to levels
reaching 100%,5 and based on our clinical experience we
recommend waiting four weeks after cessation of treatment
before requesting serum iron, transferrin/TIBC, and
transferrin saturation.
•High iron, transferrin, transferrin saturation, and serum
ferritin can be seen in acute hepatic injury due to leakage
of intracellular contents, and can incorrectly give the
impression of iron overload.5
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Box 2: Causes of iron overload6
Primary
Inherited mutations in iron regulatory genes (eg, haemochromatosis)
Secondary to other conditions/iatrogenic factors
Repeated blood transfusion (eg, beta thalassaemia, sickle cell anaemia)
Iron loading anaemias (eg, beta thalassaemia, sideroblastic anaemias, chronic haemolytic anaemia, aplastic anaemia)
Iron and iron containing supplements (enteral and parenteral)
Porphyria cutanea tarda (hepatic iron accumulation)
Investigating iron deficiency
Biochemical definitions are listed in box 3.9. Low serum ferritin
(<15 μg/L) provides absolute evidence of iron deficiency.10
Iron deficiency can result from inadequate intake of iron,
inadequate absorption or loss (through bleeding, whether frank
or occult), or a combination of both. Prevalence varies by region
and is often estimated using anaemia as an indirect indicator.9
It is quoted as 4.5%-18% in US based population studies.2
A fourth form of iron deficiency is functional. In such patients
there are sufficient iron stores but they are inadequately utilised.
Functional iron deficiency can occur in patients with acute and
chronic infectious, inflammatory, or malignant conditions.11
Inflammatory cytokines increase the synthesis of hepcidin
protein, which regulates iron. Hepcidin decreases iron absorption
from the gastrointestinal tract and impedes mobilisation of iron
from macrophages and hepatocytes.12 In certain patients—eg,
those with chronic kidney disease, ferritin below the reference
interval indicates deficient iron stores; however normal or high
values cannot exclude functional iron deficiency. A retrospective
study of more than 20 000 patient results found that serum
ferritin rises, and transferrin and serum iron fall in patients with
C reactive protein above 10 mg/L.13
Diagnosis of functional iron deficiency in patients with an
inflammatory condition can be useful in guiding further
investigations and treatment (eg, iron supplementation),
particularly when the patient has symptomatic anaemia or there
is suspected occult blood loss. This is problematic, however, as
there is no single reliable and widely available biochemical
marker for functional iron deficiency. The British Committee
for Standards in Haematology recommends percentage of
hypochromic red cells (% HRC) as the best established variable
for the diagnosis of functional iron deficiency.11 %HRC (>6%)
is recommended for diagnosis of iron deficiency in chronic
kidney disease if the sample can be processed within six hours;
however, this might be precluded by availability of laboratory
services. Reticulocyte haemoglobin content (<29 pg) is an
alternative.14 Red cell zinc protoporphyrin, soluble transferrin
receptor, and the soluble transferrin receptor log ferritin ratio
have been proposed as markers of functional iron deficiency.
They are not widely available, and soluble transferrin receptor
assays are subject to difficulties with standardisation between
laboratories.11 They are of limited use for the general clinician.
Measurement of hepcidin as a diagnostic tool is primarily
restricted to research at present; however, harmonisation of
assays and validation in the clinical setting are ongoing.
Important points to consider when interpreting
iron studies in the context of iron deficiency
- Suspected iron deficiency anaemia is best investigated
using serum ferritin. Iron deficiency is confirmed by a level
below the reference interval.
- Low serum iron cannot be interpreted in isolation because
it might be seen in infection, inflammation, and malignancy
as well as iron deficiency.5 We recommend measuring C
reactive protein if serum ferritin is normal or high with serum
iron or transferrin saturation below their respective reference
intervals.
- Transferrin saturation <16% is poorly specific, as
pregnancy, oral contraceptive use, and chronic illness can
result in low transferrin saturation without iron deficiency.15
- In general, avoid checking iron studies in those with acute
inflammatory illness or when C reactive protein is known
to be >10 mg/L. For patients with chronic inflammatory
conditions, interpretation should be performed cautiously
and results discussed with the specialist managing the
condition or haematology where there is doubt.
Monitoring response to treatment
Serial measurements of serum ferritin are commonly requested
to monitor iron status in patients who are receiving interventions
to treat deficiency or prevent iron loading— eg, venesection
and iron chelation. Which iron measure is chosen depends on
the clinical situation.
Monitor ferritin in those with haemochromatosis undergoing
venesection to deplete iron until ferritin is less than 50 μg/L,
and maintain ferritin 50-100 μg/L thereafter.1 Iron studies might
be requested to guide treatment with intravenous iron. In chronic
kidney disease, serum ferritin concentration <100 μg/L in
non-dialysed patients or <200 μg/L in chronic haemodialysis
patients is associated with a high likelihood of iron deficiency
and a potentially good response to intravenous iron treatment.14
Response to oral iron therapy in iron deficiency anaemia can
usually be confirmed by monitoring the rise in haemoglobin,2
and re-checking iron studies is not routinely required.
Patient outcome
Results in this patient showed ferritin 682 μg/L (normal range
15-200), iron 34 nmol/L (10-30), transferrin 2.0 mg/L (2-3.5),
and transferrin saturation 68% (25-45), in keeping with iron
overload. After discussing genetic testing, the patient consented
to HFE gene analysis. She was found to be homozygous for the
C282Y mutation, confirming the diagnosis of hereditary
haemochromatosis. She was referred to a specialist for
assessment and venesection therapy.
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Box 3: World Health Organization definitions of iron deficiency (2001)9
• Ferritin <15 μg/L
• OR transferrin saturation <16%
• OR haemoglobin increase of 1 g/dL after two months of iron supplementation (values vary with ethnicity and pregnancy)
• Anaemia is defined as haemoglobin <120 g/L in women and <130 g/L in men (15 years of age and above).
Education into practice
• How might your approach to testing for iron abnormalities in the presence of infection or inflammation change as a result of reading
this article?
• Is serum ferritin used routinely in your place of work as an investigation for iron deficiency?
• When and how might you contact specialist teams for assistance with interpreting iron studies results?
How patients were involved in the creation of this article
• The idea for the article was conceived following a local survey of primary and secondary care clinicians, which highlighted that many
clinicians feel uncomfortable when interpreting iron studies
• Patients with iron related disorders were informally interviewed about their experiences with iron related blood tests during investigation
and diagnosis. Some expressed the view that they would have valued more detailed explanation of their test results, which helped
inspire the content of this article
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Table
Table 1| Serum measures of iron status in states of deficiency and overload
% transferrin
saturation
Unsaturated iron binding
capacity
Transferrin/total iron binding
capacity (TIBC)
Serum ironSerum ferritin
25%-45%12-43 μmol/L (men)
13-56 μmol/L (women)
Transferrin 2.0-3.5 g/L
TIBC
45-81 μmol/L
10-30 nmol/L15-200 μg/L
(premenopausal women)
20-300 μg/L
(men and postmenopausal
women)
Normal values
↑↓↓↑↑Haemochromatosis with iron
overload
↑↓ / ↔↓ / ↔↑↑Secondary iron overload (eg,
repeated transfusion)
↔/↑↓↔↑↔Iron poisoning
↓↑↔/↑↓↓Iron deficiency
↓↓/↔↓↓↑Anaemia of chronic
disease/inflammatory response
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Figure
Fig 1 Overview of iron absorption, transport, utilisation, and excretion.
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